ArticleInternational braz j urol : official journal of the Brazilian Society of Urology
Bladder Cancer Management in Brazil's Supplementary Health System: Real-World Practice Patterns.
Article in International braz j urol : official journal of the Brazilian Society of Urology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe objective of the present study was to evaluate real-world practices of Brazilian urologists regarding bladder cancer management within the supplementary healthcare system. MATERIALS AND
methodsA cross-sectional, survey-based study was conducted among Brazilian urologists. A structured questionnaire assessed demographics, practice characteristics, and management strategies for non-muscle-invasive (NMIBC) and muscle-invasive bladder cancer (MIBC). Data were collected during the 2025 Brazilian Congress of Urology and via electronic distribution. Descriptive statistics were used, and exploratory comparisons were performed.
resultsA total of 914 urologists from 25 federative units (24 states and the federal district) participated in the study. Cystoscopy was nearly universal (93.8%), but access to enhanced imaging (17.9%) and office-based flexible cystoscopy (19.3%) was limited. In NMIBC, most urologists maintained patient care (82.9%), but management was heterogeneous. Immediate postoperative intravesical chemotherapy was rarely used. Bacillus Calmette-Guérin (BCG) was prescribed in most cases of recently treated NMIBC by 39.3% of respondents, while 54.2% referred patients for administration. Although 74.5% reported access to it, only 14.3% had availability for all patients. Preference flow analysis showed BCG as the main first-line therapy (65.4%), intravesical chemotherapy as second-line (51.2%), and pembrolizumab (31.3%) and radical cystectomy (30.2%) as third-line options. Radical cystectomy is annually performed by 65.1% of respondents; however, most reported low annual volumes, with 95% performing fewer than ten cases per year.
conclusionsBladder cancer management in the Brazilian supplementary healthcare system is heterogeneous, with important gaps in access, technology availability, and adherence to recommended practices. Despite limitations inherited to survey-based research, including potential selection bias, reliance on self-reported data, and possible overlap between public and private practice settings, these findings highlight opportunities for educational initiatives and system-level improvements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.